Early-stage life sciences investment is rebalancing after a two-year contraction, with venture capital firms concentrating funds into computational biology platforms. Platforms leveraging deep learning for target identification and lead optimization attracted $2.4 billion in private equity funding during the first half of the year.
Compressing Preclinical Timelines
Traditional drug discovery cycles averaging four to six years for target validation are being reduced to under 18 months in active clinical trials using predictive structural biology models. Investors are requiring portfolio companies to demonstrate wet-lab validation early in funding rounds, prioritizing platforms that demonstrate clear hit-to-lead success ratios over speculative broad-spectrum libraries.